Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Altimmune (ALT) to $14 from $15 and keeps an Outperform rating on the shares. The firm says it looks forward to the oral late-breaking presentation of pemvidutide’s Phase 2b data at the Liver Meeting with 48-week data on track for this quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune Reports Q3 2025 Financial and Business Progress
- Altimmune’s Earnings Call: Financial Growth and Clinical Progress
- Altimmune’s Clinical Progress and Financial Maneuvers Justify Hold Rating Amid Transitional Phase
- Altimmune Enters New Equity Distribution Agreement
- Altimmune files $400M mixed securities shelf